The New York Times featured ACR DSI Chief Science Officer Keith Dreyer, DO, PhD, FACR, in an article about using artificial intelligence (AI) in medicine and the U.S. Food and Drug Administration’s (FDA) role in regulating the technology.
The article highlights a study that Dr. Dreyer and colleagues authored that found that out of the 188 FDA-cleared AI programs that were cleared through 2021, only one described the geographic and racial breakdown of the patients the program was trained on, and most of those programs were tested on 500 or fewer cases. That’s simply not enough to justify widely deploying them, Dr. Dreyer and his co-authors argued.
However, the ACR Data Science Institute is working on an update to AI Central, our FDA-cleared Imaging AI product directory, to increase transparency about these AI algorithms — including how they were developed and validated — with the help of manufacturers willing to voluntarily share that information.
That way, for example, a radiologist could look up how many pediatric cases a program was trained on to inform them of blind spots that could potentially affect care, the New York Times reported.
Read more on The New York Times.